期刊文献+

重组人干扰素α-2b-卡介苗(hIFN-α-2b-BCG)药物敏感性分析

Analysis on drug sensitivity tests of recombinant hIFN-α-2b BCG
下载PDF
导出
摘要 通过BACTEC MGITTM 960全自动分枝杆菌培养鉴定/药敏仪对重组人干扰素α-2b-卡介苗(hIFN-α-2b-BCG)菌株进行利福平等10种抗菌药物的敏感性试验,以野生BCG作对照观察药物对重组BCG菌株活性的潜在影响.结果发现:重组人干扰素α-2b-卡介苗在系统感染上对喹酮类的氧氟沙星、环丙沙星敏感,对氨基糖苷类药物的庆大霉素和卡那霉素耐药.在抗结核类药物中,除对吡嗪酰胺耐药外,对利福平等其他几种抗生素均敏感.因尿液回收率高,几乎所有的抗菌药物都对膀胱中的菌株有影响. To understand the situation of drug resistance of hlFN-α-2b BCG, in order to explore the curative effects of antibiotics on adverse reaction caused by IFN-α-2b-BCG during treating bladder carcinoma and their impact on an-ti-tumor effect of recombinant IFN-α-2b-BCG, wild BCG served as control, 10 kinds of antibacterial drugs including rifampicin, potentially effective against the IFN-α-2b-BCG, were measured in vitro by the BACTEC 960TB method, to observe the potential impact of antibiotics on the activity of recombinant BCG strains. The results showed that IFN-α-2b-BCG was susceptible to quinolones in systemic infections but resistant to some aminoglycosides. It was re- sistant to pyrazinamide but showed good susceptibility toward the other antituberculosis drugs tested. Most antibac- terials may interfere with IFN-α-2b-BCG in the bladder because of high urinary recovery.
出处 《天津师范大学学报(自然科学版)》 CAS 2012年第3期75-77,共3页 Journal of Tianjin Normal University:Natural Science Edition
基金 国家自然科学基金(30872587) 天津卫生局重点攻关项目(11KJ147) 天津市科技支撑计划重大项目(07ZCKFSH03200) 国家科技部"十一五"重大专项新药创建课题(2009ZX09103-699)
关键词 膀胱肿瘤 重组BCG 人干扰素Α-2B 免疫反应 耐药性 urinary bladder neoplasms recombinant BCG vaccine IFN-α-2b immunotherapy drug resistance
  • 相关文献

参考文献3

二级参考文献20

  • 1刘春雨,韩瑞发,马腾骧,畅继武,韩育植,隋志芳.phIFN-α-2B穿梭质粒在卡介苗中的表达[J].中华泌尿外科杂志,2006,27(S1):12-14. 被引量:8
  • 2董亚利,白景文,沈伟,曾嘉,韩瑞发.BCG对体外培养人癌细胞直接作用的扫描电镜观察[J].天津医科大学学报,1995,1(2):23-25. 被引量:3
  • 3胡端敏,王少峰,冯一中.MMP-7与Fas蛋白在胃癌组织中的表达及意义[J].世界华人消化杂志,2006,14(33):3237-3240. 被引量:4
  • 4Meyer JP, Persad R, GiUatt DA. Use of bacille Cahnette-Guerin in superficial bladder cancer. Postgrad Med J, 2002, 78 ( 11 ) : 449-.454.
  • 5Naitoh J, Franklin J, O'Donnell MA, et al. Interferon alpha for the treatment of superficial bladder cancer. Adv Exp Meal Biol, 1999, 462 : 371-386.
  • 6Gan YH, Zhang Y, Khoo HE, et al. Antitumor immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer. Eur J Cancer, 1999, 35(7): 1123-1129.
  • 7Luo Y, Chen X, O'Donnell MA. Role of Thl and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine, 2003, 21 ( 1 ) : 17-26.
  • 8Luo Y, Chen X, Downs TM, et al. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis Bacillus Calmette-Guerin immuno-therapy. J Immunol, 1999, 162(4) : 2399-2405.
  • 9Murray P J, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette- Guerin strains that secrete cytokines. Prec Nail Acad Sci USA, 1996, 93(5): 934-939.
  • 10Santhanam S, Decatris M, O'Byrne K. Potential of interferon-alpha in solid turnouts: part 2. BioDrugs, 2002, 16(5) : 349-372.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部